Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

NEW BRUNSWICK, N.J., March 17, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 14th, to review first-quarter results.  Dominic Caruso, Vice President, Finance and Chief Financial Officer and Louise Mehrotra, Vice President, Investor Relations, will host the call.

Investors and other interested parties may access the conference call in the following ways:

  • At Johnson & Johnson's website: www.investor.jnj.com. This earnings webcast is optimized for mobile streaming on iOS devices such as iPhones, iPods, and iPads. A webcast and podcast replay will be available approximately two hours after the conference call concludes.
  • By telephone: For both "listen-only" participants and those financial analysts who wish to take part in the question-and-answer portion of the call, the telephone dial-in number in the U.S. is 866-527-6580. For participants outside the U.S., the dial-in number is 928-328-8470. The conference ID number for all callers is 6366816. A replay of the conference call will be available beginning at approximately 1:00 p.m. on Apr. 14, 2015, and ending at approximately 12:00 a.m. on Apr. 22, 2015. The replay dial-in number for U.S. participants is 855-859-2056. For participants outside the U.S., the replay dial-in number is (404) 537-3406. The replay conference ID number for all callers is 6366816.
  • Presentation materials will be available on www.investor.jnj.com.

About Johnson & Johnson

Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 126,500 employees at more than 265 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/johnson--johnson-to-host-investor-conference-call-on-first-quarter-results-300051732.html

SOURCE Johnson & Johnson

Suggested Articles

The lawsuit is part of a years-long battle between the Cochrane Collaboration and Roche around Tamiflu's use against pandemic influenza.

Takeda forged a feasibility pact to see whether it could pair a plasma-based therapy with Elektrofi's microparticle delivery tech.

Sanofi's Dupixent is set to reach $12.5 billion in peak sales, Jefferies analysts wrote, affirming CEO Paul Hudson's focus on the immunology med.